Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine plus Memantine in Alzheimer's Disease
NCT00305903Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Safety and tolerability of treatment with memantine and rivastigmine. Started Mar 2006; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00305903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305903.